ACT-709478 for oral use
DrugHard gelatin capsules for oral administration formulated at strengths of 10 mg and 100 mg
NCT Number: NCT03239691
The main study objective is to assess the effect of ACT-709478 in male and female subjects with photosensitive epilepsy following single dose administration
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Phase 2
HOSP - Bicêtre Neurologie, Le Kremlin-Bicêtre, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Hard gelatin capsules for oral administration formulated at strengths of 10 mg and 100 mg
Matching placebo available as matching capsules for oral administration
Time frame: From Day 2 to Day 10
Positive response described as complete suppression of photoparoxysmal response (PPR) or a clinically relevant reduction in the standardized photosensitive range (SPR)
Time frame: From Day 2 to Day 10
Defined by the first time point after ACT-709478 administration at which complete suppression of PPR or clinically relevant reduction in SPR is achieved
Time frame: From Day 2 to Day 10
Defined as the time elapsed between the time point of onset of the positive response and the last time point of the positive response after ACT-709478 administration
Time frame: From Day 2 to Day 10
Defined as the largest reduction in SPR achieved at any time point compared to baseline during the positive response after ACT-709478 administration
Time frame: From Day 2 to Day 10
Idorsia Pharmaceuticals Ltd.
Industry
A Phase 2a, Multi-center, Single-blind, Within-subject, Placebo-controlled Study to Assess the Pharmacodynamics of ACT-709478 in Subjects With Photosensitive Epilepsy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06525649
Brain Diseases, Central Nervous System Diseases
Little Rock, Arkansas, United States
View Trial DetailsNCT03790137
Brain Diseases, Central Nervous System Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT03580707
Brain Diseases, Central Nervous System Diseases
St Louis, Missouri, United States
View Trial DetailsNCT00609245
Brain Diseases, Central Nervous System Diseases
Chesterfield, Missouri, United States
View Trial Details